文献速递肾小球疾病急性肾损伤

抗MPO与抗PR3抗体预测ANCA相关血管炎肾脏复发

Anti-myeloperoxidase and proteinase 3 antibodies for nephritis flare prediction in anti-neutrophil cytoplasmic antibody-associated vasculitis.
PubMed 文献 · Nephrol Dial Transplant · 2022-01-01

本研究回顾性纳入113例经肾活检证实的寡免疫坏死性肾小球肾炎的AAV患者,评估MPO和PR3抗体滴度对肾脏疾病活动及复发的预测价值。结果显示复发前MPO抗体水平及ΔMPO均显著升高,MPO抗体预测肾脏复发的AUC为0.82,PR3抗体在复发前亦显著升高。

要点

  • 复发前3个月MPO抗体水平显著高于未复发者,AUC 0.82。
  • ΔMPO抗体变化对肾脏复发有预测价值,AUC 0.76。
  • PR3抗体在复发前约2.8个月显著升高。

核心结论

  • MPO水平监测和PR3测量是预测AAV肾病患者肾脏复发的有用且敏感的工具,也是肾脏疾病活动性的相关替代标志物。

研究设计与样本

  • 回顾性研究,纳入113例来自七家西班牙医院的AVV患者,均有肾活检证实的寡免疫坏死性肾小球肾炎。
  • 主要纳入标准为使用多重流式免疫分析法评估MPO抗体,并使用免疫分析化学发光法测量PR3抗体,所有参与中心使用相同的值范围。

主要发现

  • 复发前3±1.2个月,复发患者的血清MPO抗体更高(19.2±12.2 vs 3.2±5.1抗体指数;P<0.001)。
  • 复发前3个月MPO抗体预测肾脏复发的AUC为0.82(95%CI 0.73-0.92;P<0.001)。
  • ΔMPO抗体(复发前6个月抗体滴度变化)在复发患者中更高(8.3±12 vs 0.9±3.1 AI;P=0.001),其AUC为0.76(95%CI 0.63-0.88;P<0.001)。
  • PR3患者肾脏复发的阳性预测值为100%,PR3阳性滴度患者的阴性预测值为57.1%。
  • 复发前2.8±1.4个月,复发患者的血清PR3抗体更高(58.6±24.6 vs 2.0±0.6 AI;P<0.001)。

关键数值与推荐

  • MPO抗体预测肾脏复发AUC 0.82(95%CI 0.73-0.92;P<0.001)。
  • ΔMPO预测肾脏复发AUC 0.76(95%CI 0.63-0.88;P<0.001)。
  • PR3阳性患者肾脏复发阳性预测值100%,阴性预测值57.1%。

临床怎么用

  • 在AAV伴肾脏疾病患者随访中,可监测MPO和PR3抗体水平以辅助预测肾脏复发。

局限性

  • 回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The value of myeloperoxidase (MPO) and proteinase 3 (PR3) antibody titres in the assessment of renal disease activity and flare prediction in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is not well known. METHODS: We performed a retrospective study including 113 AVV patients with renal biopsy-proven pauci-immune necrotizing glomerulonephritis from seven Spanish hospitals. The main inclusion criteria were assessment of MPO antibodies using multiplex flow immunoassay and PR3 antibody measurements using immunoassay chemiluminescence with an identical range of values for all participating centres. RESULTS: Serum MPO antibodies 3 ± 1.2 months before relapse were higher in patients who relapsed [19.2 ± 12.2 versus 3.2 ± 5.1 antibody index (AI); P < 0.001]. The discrimination value of MPO antibodies 3 months before renal relapse had an area under the receiver operating characteristics curve (AUC) of 0.82 [95% confidence interval (CI) 0.73-0.92; P < 0.001]. ΔMPO antibodies (change in antibodies titration 6 months before relapse) were higher in patients who relapsed (8.3 ± 12 versus 0.9 ± 3.1 AI; P = 0.001). The discrimination value of ΔMPO had an AUC of 0.76 (95% CI 0.63-0.88; P < 0.001). The positive predictive value of renal relapse in PR3 patients is 100% and the negative predictive value of renal relapse in patients with PR3-positive titres is 57.1%. Serum PR3 antibodies were higher in patients who relapsed 2.8 ± 1.4 months before relapse (58.6 ± 24.6 versus 2.0 ± 0.6 AI; P < 0.001). CONCLUSIONS: MPO level monitoring using multiplex flow immunoassay and PR3 measurements using immunoassay chemiluminescence are useful and sensitive tools for the prediction of renal relapse in the follow-up of AAV patients with renal disease and relevant surrogate markers of renal disease activity.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Rodríguez E, Latzke B, Sierra M, et al. Anti-myeloperoxidase and proteinase 3 antibodies for nephritis flare prediction in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant. 2022. PMID: 33533909. doi:10.1093/ndt/gfab020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。